论文部分内容阅读
目的 研究１５３ＳＭＥＤＴＭＰ 与参麦注射液联合治疗骨转移癌镇痛及在治疗骨病变基础上提高免疫功能、防止骨髓抑制的效果。方法 ７６ 例骨转移癌患者采用随机分组对照研究，观察治疗前后骨痛和骨病变疗效及提高免疫功能、防止骨髓抑制效果。结果 镇痛有效率分别为８９ ％ 、７９ ％ ，骨病变缓解率分别为３９ ％ 、３４ ％ ， 二组差异无显著性（ Ｐ＞０－０５） ；Ｔ４／Ｔ８ 比值、ＮＫ 值治疗后比较差异有显著性（ Ｐ＜０－０１） ；防止白细胞、血小板下降，两组比较差异有显著性（ Ｐ＜ ０－０５） 。结论 联合治疗法疗效显著，安全可靠，具有一定临床应用价值。
Objective To study the effect of 153SMEDTMP combined with Shenmai injection in the treatment of bone metastasis cancer analgesia and to improve immune function and prevent bone marrow suppression in the treatment of bone lesions. Methods A total of 76 patients with bone metastases were randomized into controlled trials to observe the effects of bone pain and bone lesions before and after treatment, and to improve immune function and prevent bone marrow suppression. Results The analgesic efficacy rates were 89% and 79%, respectively, and the bone disease remission rates were 39% and 34% respectively. There was no significant difference between the two groups (P>0-05). The difference of T4/T8 ratio and NK value after treatment was significant. Significant (P <0-01); to prevent white blood cell, platelet decline, the difference between the two groups was significant (P <0-05). Conclusion The combination therapy is effective, safe and reliable. It has certain clinical application value.